A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

NCT ID: NCT05467176

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

999 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-04

Study Completion Date

2028-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective observational cohort study will be conducted in patients who are initiating treatment or have initiated treatment with ORGOVYX within the 1 month prior to the time of study enrollment and who remain on treatment at the time of enrollment. The decision to initiate treatment with ORGOVYX should be made prior to study enrollment. The study is designed to better understand the actual experience of patients with prostate cancer treated with ORGOVYX by collecting data on treatment patterns, adherence, and selective safety data. Additionally, a better understanding of the trajectory of patients with prostate cancer following cessation of ORGOVYX therapy will be gained by observing the clinical course of the disease, health outcomes, and health-related quality-of-life (HRQoL) in these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Prostate Cancer

Patients with prostate cancer who are initiating treatment or have initiated treatment with ORGOVYX (per label instructions) within 1 month prior to enrollment and who remain on treatment at the time of enrollment.

Relugolix

Intervention Type DRUG

Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Relugolix

Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TAK-385 MVT-601 RVT-601 T-1331285 ORGOVYX

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are diagnosed with prostate cancer and initiating treatment with ORGOVYX at the time of enrollment or within 1 month prior to enrollment and who remain on treatment at enrollment
* Patients who are willing and able to complete PRO assessments during the study
* Patients who have reviewed and signed the informed consent form (ICF)

Exclusion Criteria

* Patients with a history of surgical castration
* Patients with a medical or psychiatric condition that precludes participation in the opinion of the treating physician
* Patients whose original treatment plan is intended to be less than a total of 4 months of ORGOVYX
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sumitomo Pharma America, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Sumitomo Pharma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Urology Centers of Alabama

Homewood, Alabama, United States

Site Status

Urology Associates of Mobile

Mobile, Alabama, United States

Site Status

Dignity Health

Phoenix, Arizona, United States

Site Status

Arizona Urology Specialists, PLLC

Tucson, Arizona, United States

Site Status

Arkansas Urology Research Center

Little Rock, Arkansas, United States

Site Status

City of Hope

Duarte, California, United States

Site Status

Urology Associates of Central California

Fresno, California, United States

Site Status

UCSD

La Jolla, California, United States

Site Status

USC Norris Cancer Center

Los Angeles, California, United States

Site Status

Tower Urology

Los Angeles, California, United States

Site Status

VA Greater Los Angeles Medical Center

Los Angeles, California, United States

Site Status

Tri Valley Urology

Murrieta, California, United States

Site Status

Genesis Research LLC

San Diego, California, United States

Site Status

Golden State Urology

Stockton, California, United States

Site Status

Rocky Mountain Regional VA Medical Center

Aurora, Colorado, United States

Site Status

The Urology Center of Colorado

Denver, Colorado, United States

Site Status

Banner MD Anderson Cancer Center

Greeley, Colorado, United States

Site Status

Colorado Urology

Lakewood, Colorado, United States

Site Status

Urology Associates

Lone Tree, Colorado, United States

Site Status

The Stamford Hospital

Stamford, Connecticut, United States

Site Status

Urologic Surgeons of Washington

Washington D.C., District of Columbia, United States

Site Status

MemorialCare, Long Beach Memorial Medical Center

Washington D.C., District of Columbia, United States

Site Status

Bay Pines VA Healthcare System

Bay Pines, Florida, United States

Site Status

Manatee Medical Research Institute, LLC

Bradenton, Florida, United States

Site Status

Advanced Urology Institute

Daytona Beach, Florida, United States

Site Status

Memorial Healthcare System

Hollywood, Florida, United States

Site Status

United Medical Group

Miami, Florida, United States

Site Status

SG Research LLC

Miami, Florida, United States

Site Status

Genesis Care USA

Naples, Florida, United States

Site Status

Florida Urology Partners, LLP

Tampa, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Georgia Urology

Decatur, Georgia, United States

Site Status

PRiSMS Group LLC

Arlington Heights, Illinois, United States

Site Status

Associated Urological Specialists

Chicago Ridge, Illinois, United States

Site Status

Northwestern University

Evanston, Illinois, United States

Site Status

UroPartners Research

Glenview, Illinois, United States

Site Status

Comprehensive Urologic Care

Lake Barrington, Illinois, United States

Site Status

Duly Health and Care

Lisle, Illinois, United States

Site Status

Advanced Urology Associates

New Lenox, Illinois, United States

Site Status

Urology of Indiana

Carmel, Indiana, United States

Site Status

Urologic Specialists of Northwest Indiana

Merrillville, Indiana, United States

Site Status

Greater Regional Health

Creston, Iowa, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Wichita Urology Group, P.A.

Wichita, Kansas, United States

Site Status

Baptists Health Lexington

Lexington, Kentucky, United States

Site Status

Southern Urology

Lafayette, Louisiana, United States

Site Status

John Hopkins

Baltimore, Maryland, United States

Site Status

Chesapeake Urology Associates

Baltimore, Maryland, United States

Site Status

Maryland Oncology Hematology

Columbia, Maryland, United States

Site Status

Medstar Georgetown University Hospital

Columbia, Maryland, United States

Site Status

Michigan Institute of Urology

Troy, Michigan, United States

Site Status

GenesisCare USA

Troy, Michigan, United States

Site Status

Minnesota Urology

Woodbury, Minnesota, United States

Site Status

Specialty Clinical Research of St. Louis

St Louis, Missouri, United States

Site Status

Summit Medical Group, P.A. | New Jersey Urology

Berkeley Heights, New Jersey, United States

Site Status

AtlanticCare Cancer Institute

Egg Harbor, New Jersey, United States

Site Status

The Valley Hospital

Paramus, New Jersey, United States

Site Status

Regional Cancer Care Associates

Teaneck, New Jersey, United States

Site Status

Crystal Run Healthcare

Middletown, New York, United States

Site Status

Optum Medical Care, P. C.

Mount Kisco, New York, United States

Site Status

Mount Sinai Hospital

New York, New York, United States

Site Status

SUNY Upstate Medical Institution

Syracuse, New York, United States

Site Status

Associated Medical Professionals of NY, PLLC

Syracuse, New York, United States

Site Status

Mohawk Valley Health Services

Utica, New York, United States

Site Status

DJL Clinical Research, PLLC

Charlotte, North Carolina, United States

Site Status

Durham VA Healthcare

Durham, North Carolina, United States

Site Status

GenesisCare USA

Greenville, North Carolina, United States

Site Status

Associated Urologist of North Carolina

Raleigh, North Carolina, United States

Site Status

Clinical Inquest Center Ltd

Beavercreek, Ohio, United States

Site Status

NEO Urology Associates, Inc.

Boardman, Ohio, United States

Site Status

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Site Status

University Hospitals

Cleveland, Ohio, United States

Site Status

Central Ohio Urology Group

Gahanna, Ohio, United States

Site Status

Premier Clinical Research LLC dba STAT Research

Springboro, Ohio, United States

Site Status

The University of Toledo

Toledo, Ohio, United States

Site Status

Oregon Urology Institute

Springfield, Oregon, United States

Site Status

Spokenword Clinical Trials

Easton, Pennsylvania, United States

Site Status

Keystone Urology Specialist

Lancaster, Pennsylvania, United States

Site Status

GU, Inc.

Latrobe, Pennsylvania, United States

Site Status

Carolina Urologic Research Center, LLC

Myrtle Beach, South Carolina, United States

Site Status

Lowcountry Urology Clinics

North Charleston, South Carolina, United States

Site Status

The Conrad Pearson Clinic

Germantown, Tennessee, United States

Site Status

University of Tennessee Medical Center

Knoxville, Tennessee, United States

Site Status

Urology Austin

Austin, Texas, United States

Site Status

Hmu, Crc Llc

Houston, Texas, United States

Site Status

MD Anderson

Houston, Texas, United States

Site Status

New Horizon Medical Group, LLC

Houston, Texas, United States

Site Status

Ascend Pharma Holdings

Houston, Texas, United States

Site Status

Urology San Antonio, P.A. dba USA Clinical Trials

San Antonio, Texas, United States

Site Status

The Urology Place

San Antonio, Texas, United States

Site Status

Potomac Urology Center, PC

Alexandria, Virginia, United States

Site Status

MedAtlantic

Richmond, Virginia, United States

Site Status

Urology of Virginia, PLLC

Virginia Beach, Virginia, United States

Site Status

Spokane Urology, P.S.

Spokane, Washington, United States

Site Status

Wisconsin Institute of Urology

Neenah, Wisconsin, United States

Site Status

Aspirus

Wausau, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Spratt DE, Dorff T, McKay RR, Lowentritt BH, Fallick M, Gatoulis SC, Flanders SC, Ross AE. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol. Future Oncol. 2024 Apr;20(12):727-738. doi: 10.2217/fon-2023-0748. Epub 2024 Mar 15.

Reference Type DERIVED
PMID: 38488039 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MVT-601-058

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pre-Prostatectomy Celecoxib or Placebo
NCT02840162 TERMINATED PHASE2
SpaceOAR System Pivotal Study
NCT01538628 COMPLETED PHASE3